BRPI0819920A2 - Compostos orgânicos - Google Patents

Compostos orgânicos

Info

Publication number
BRPI0819920A2
BRPI0819920A2 BRPI0819920-5A BRPI0819920A BRPI0819920A2 BR PI0819920 A2 BRPI0819920 A2 BR PI0819920A2 BR PI0819920 A BRPI0819920 A BR PI0819920A BR PI0819920 A2 BRPI0819920 A2 BR PI0819920A2
Authority
BR
Brazil
Prior art keywords
organic compounds
compounds
organic
Prior art date
Application number
BRPI0819920-5A
Other languages
English (en)
Inventor
Peter Herold
Robert Mah
Vincenzo Tschinke
Stjepan Jelakovic
Stefan Stutz
Dirk Behnke
Nathalie Jotterand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0819920A2 publication Critical patent/BRPI0819920A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0819920-5A 2007-12-13 2008-12-12 Compostos orgânicos BRPI0819920A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07150019 2007-12-13
PCT/EP2008/067407 WO2009074674A2 (en) 2007-12-13 2008-12-12 Trisubstituted piperidines as renin inhibitors

Publications (1)

Publication Number Publication Date
BRPI0819920A2 true BRPI0819920A2 (pt) 2015-05-19

Family

ID=39709362

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819920-5A BRPI0819920A2 (pt) 2007-12-13 2008-12-12 Compostos orgânicos

Country Status (12)

Country Link
US (1) US20110009399A1 (pt)
EP (1) EP2231677A2 (pt)
JP (1) JP2011506401A (pt)
KR (1) KR20100097731A (pt)
CN (1) CN101896490A (pt)
AR (1) AR069677A1 (pt)
AU (1) AU2008334555A1 (pt)
BR (1) BRPI0819920A2 (pt)
CA (1) CA2708570A1 (pt)
EA (1) EA201000889A1 (pt)
TW (1) TW200940547A (pt)
WO (1) WO2009074674A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708866A1 (en) 2007-12-19 2009-06-25 Hiroyuki Nakahira Bicyclic heterocyclic derivative
KR20120109292A (ko) 2009-06-24 2012-10-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-치환-시클릭 아미노 유도체
WO2011057382A1 (en) * 2009-10-13 2011-05-19 Merck Frosst Canada Ltd. Spirocyclic piperidine derivatives useful as renin inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200513461A (en) * 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
AU2006268724B2 (en) * 2005-07-14 2011-06-02 F. Hoffmann-La Roche Ag Indol-3-carbonyl-spiro-piperidine derivatives as V1A receptor antagonists

Also Published As

Publication number Publication date
US20110009399A1 (en) 2011-01-13
WO2009074674A2 (en) 2009-06-18
CA2708570A1 (en) 2009-06-18
JP2011506401A (ja) 2011-03-03
WO2009074674A3 (en) 2009-07-30
AU2008334555A1 (en) 2009-06-18
AR069677A1 (es) 2010-02-10
TW200940547A (en) 2009-10-01
EA201000889A1 (ru) 2011-02-28
EP2231677A2 (en) 2010-09-29
CN101896490A (zh) 2010-11-24
KR20100097731A (ko) 2010-09-03

Similar Documents

Publication Publication Date Title
DK2240490T3 (da) Organiske forbindelser
BRPI0817434A2 (pt) Composto orgânicos
BRPI0811562A2 (pt) Compostos orgânicos
BRPI0922351A2 (pt) compostos orgânicos
BRPI0922700A2 (pt) Compostos orgânicos
BRPI0922808A2 (pt) compostos orgânicos
BRPI0922131A2 (pt) Compostos orgânicos
BRPI0922809A2 (pt) compostos orgânicos
BRPI0922348A2 (pt) Compostos orgânicos
BRPI0913966A2 (pt) compostos orgânicos
BRPI0914698A2 (pt) compostos orgânicos
BRPI0909417A2 (pt) compostos orgânicos
BRPI0915018A2 (pt) compostos orgânicos
BRPI0718874A2 (pt) Compostos orgânicos
NO20084803L (no) organiske forbindelser
BRPI0718478A2 (pt) Compostos orgânicos
DK2310359T3 (da) Organiske forbindelser
BRPI0917574A2 (pt) compostos orgânicos
BRPI0921826A2 (pt) compostos orgânicos
BRPI0907611A2 (pt) Compostos orgânicos
BRPI0821401A2 (pt) Compostos orgânicos
BRPI0813500A2 (pt) Compostos antivirais
ATE502948T1 (de) Substituierte bicyclolactamverbindungen
BRPI0821086A2 (pt) Compostos inseticidas
BRPI0712902A2 (pt) compostos orgânicos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.